Mavorixafor (Xolremdi) drug introduction

OLREMDI (mavorixafor) is a major innovation in the medical field. This once-daily oral medication provides a new treatment option for patients 12 years of age and older. It is effective against warts, hypogammaglobulinemia, many infections, and the rare immunodeficiency disorder myelodysplastic syndrome.

The core mechanism of XOLREMDI is that it acts as a selective antagonist of CXCchemokine receptor4 (CXCR4). This drug was carefully developed by X4 Pharmaceuticals, a well-known American biopharmaceutical company. It effectively increases circulating mature neutrophil and lymphocyte counts by targeting dysfunction of the CXCR4 pathway. It is worth noting that dysfunction of the CXCR4 pathway is the potential root cause of WHIM syndrome.

Over the past few years, mavorixafor has been recognized by international authorities. In 2018, the U.S. Food and Drug Administration (FDA) listed it as a treatment WHIM syndrome, and in July 2019, the European Commission also granted the drug orphan drug status.

Meanwhile, X4 Pharmaceuticals is not alone in its journey of drug development and commercialization. It has reached an in-depth cooperation with China's leading biotechnology company Abbisko Therapeutics. The two parties joined forces in July 2019 and are committed to developing and promoting mavorixafor in Greater China, as well as cooperation on checkpoint inhibitors and other anti-cancer drugs.

Recently, FDA has approved XOLREMDI4WHIM phase study >™ will be used in clinical trials for the treatment of WHIM syndrome in 2024 and 4 months. X4 Pharmaceuticals also expects to obtain further approval for mavorixafor from the European Medicines Agency (EMA) at the beginning of 2025.

From the appearance, XOLREMDI™ takes the form of an opaque hard gelatin oral capsule. The white capsule body complements the light blue capsule cover. Each capsule contains 100mg of pharmaceutical ingredients.

In patients with WHIM syndrome, gain-of-function mutations in the CXCR4 receptor gene enhance CXCL12 reactivity, leading to excessive retention of white blood cells in the bone marrow. The miraculous thing about mavorixafor is that it can reduce the response of wild-type and mutant CXCR4 variants to CXCL12, thereby promoting neutrophils and lymphocytes to enter the peripheral circulation more effectively, thereby improving the patient's immune status.

How effective is Mavorixafor (Xolremdi) in the treatment of WHIM syndrome

In the WHIM syndrome patient population, gain-of-function mutations in the CXCR4 receptor gene are a critical issue. This mutation abnormally enhancesCXCL12reactivity, causing excessive retention of white blood cells in the bone marrow. This phenomenon severely affects the patient's immune system function because neutrophils and lymphocytes cannot enter the peripheral circulation normally, thus weakening the body's resistance to infection and disease.

In order to verify the efficacy and safety ofmavorixafor, the third phase clinical trial of WHIM came into being. This was a global, rigorously designed study that was randomized, double-blind, placebo-controlled and lasted a full 52 weeks. With the joint efforts of multiple research centers, 31 patients aged 12 years and above who were diagnosed with WHIM syndrome participated in this trial.

The trial's primary endpoints include improvements in absolute neutrophil counts (ANC) and absolute lymphocyte counts (ALC), as well as reductions in infections. The results showed that compared with the placebo group, patients treated with mavorixafor maintained above the threshold time (i.e., ANC remained at 500 cells pan>/microliters and above, ALCmaintained at 1000cells/microliters and above) with a significant increase.

In addition to improvements in a single blood measure, the drug's efficacy was comprehensively assessed through a composite endpoint that took into account the total infection score and the total wart change score. Encouragingly, patients treated with mavorixafor experienced a nearly 40% reduction in overall infection scores and a significant 60% reduction in annual infection rates compared with patients taking placebo. However, it is worth noting that this treatment has not shown significant results in improving warts.

During the trial, although some adverse reactions were observed, such as thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting and dizziness, most of these reactions were within the acceptable range and did not seriously affect the patient's health. Overall, mavorixafor has shown significant efficacy in improving the immune function of patients with WHIM syndrome, and has a good safety profile, bringing new treatment options to patients.